Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04357717 · ClinicalTrials.gov registry record
ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting
A clinical trial, sponsored by Exosome Diagnostics.
- Terminated
- Registry status
- 150
- Enrollment target
NCT04357717: Clinical Trial study, sponsored by Exosome Diagnostics.
NCT04357717 is a clinical trial that was terminated before completion, run by Exosome Diagnostics. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04357717 was terminated before completion, sponsored by Exosome Diagnostics.
- TERMINATED
- Registry status
- 150 participants
- Enrollment target
Study Summary
The study is designed to confirm the performance of the ExoDx Prostate test in prior negative biopsy patients now presenting for a repeat prostate biopsy. Note: ExoDx Prostate test results are collected for correlation to biopsy results and are not disclosed to the physician or study subject.
Interventions
- DIAGNOSTIC_TEST ExoDx Prostate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2020-03-15 |
| Est. Completion | 2021-09-01 |
Why NCT04357717 stopped before completion
NCT04357717 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which ExoDx Prostate is the first listed.
NCT04357717 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04357717 about?
NCT04357717 is a clinical study titled "ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting". The study is designed to confirm the performance of the ExoDx Prostate test in prior negative biopsy patients now presenting for a repeat prostate biopsy. Note: ExoDx Prostate test results are collected for correlation to biopsy results and are not disclosed to the physician or study subject.
What is the current status of trial NCT04357717?
This trial is currently terminated. The enrollment target is 150 participants. The study started on 2020-03-15. Estimated completion is 2021-09-01.
What interventions are being tested in trial NCT04357717?
The interventions under investigation include: ExoDx Prostate (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04357717?
This trial is sponsored by Exosome Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI